ACI-35 Liposomal Vaccine

Migration, Crosslink

📖

ACI-35 Liposomal Vaccine

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-aci-35-liposomal-vacci

📖 Wiki Page

therapeutic2629 wordssynced 2026-04-02

ACI-35 Liposomal Vaccine

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ACI-35 Liposomal Vaccine</th>
</tr>
<tr>
<td class="label">Candidate</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>Active vaccine (pSer396/404)</td>
</tr>
<tr>
<td class="label">ACI-35.030</td>
<td>Enhanced formulation</td>
</tr>
<tr>
<td class="label">Anti-tau antibodies</td>
<td>Passive immunization</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Infrequent (monthly to yearly)</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Long-lasting immunity</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Lower long-term cost</td>
</tr>
<tr>
<td class="label">Flexibility</td>
<td>Memory responses</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Immediate effect</td>
</tr>
<tr>
<td class="label">Consistency</td>
<td>Defined dosing</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Reversible</td>
</tr>
</table>

Overview

...

ACI-35 Liposomal Vaccine

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ACI-35 Liposomal Vaccine</th>
</tr>
<tr>
<td class="label">Candidate</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>Active vaccine (pSer396/404)</td>
</tr>
<tr>
<td class="label">ACI-35.030</td>
<td>Enhanced formulation</td>
</tr>
<tr>
<td class="label">Anti-tau antibodies</td>
<td>Passive immunization</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Infrequent (monthly to yearly)</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Long-lasting immunity</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Lower long-term cost</td>
</tr>
<tr>
<td class="label">Flexibility</td>
<td>Memory responses</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Immediate effect</td>
</tr>
<tr>
<td class="label">Consistency</td>
<td>Defined dosing</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Reversible</td>
</tr>
</table>

Overview

ACI-35 is a liposome-based therapeutic vaccine targeting phosphorylated tau proteins, developed by [AC Immune](/companies/ac-immune) SA in collaboration with [Janssen](/companies/janssen) Pharmaceuticals. It represents one of the most advanced active immunization strategies for Alzheimer's disease (AD) and other tauopathies, including progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and frontotemporal dementia (FTD) [1]. Unlike passive antibody therapies that require repeated infusions, ACI-35 stimulates the patient's own immune system to generate anti-tau antibodies, potentially providing sustained protection with periodic booster vaccinations. [@immune2023]

The vaccine targets phosphorylated tau at the Ser396/404 epitope, which is a key pathological modification found in neurofibrillary tangles (NFTs) in AD and related tauopathies. By generating antibodies against these pathological tau species, ACI-35 aims to slow or halt the progression of tau-driven neurodegeneration. This page provides a comprehensive overview of ACI-35's mechanism of action, clinical development, comparison to other tau immunotherapies, and future directions [2]. [@pulanco2022]

Mechanism of Action

Target Selection: Phosphorylated Tau

[Tau](/proteins/tau) protein is a microtubule-associated protein that stabilizes neuronal axons under normal conditions. In AD and other tauopathies, tau becomes hyperphosphorylated, aggregates into neurofibrillary tangles, and propagates throughout the brain in a pattern that correlates with clinical decline. The phosphorylation at serine 396 and serine 404 (pSer396/pSer404) is particularly relevant because: (1) these sites are among the earliest and most extensively modified in AD; (2) antibodies against pSer396/404 preferentially recognize pathological tau over normal tau; and (3) this epitope is accessible for antibody binding in both extracellular tangles and intracellular tau aggregates [3]. [@schindowski2006]

The rationale for targeting phosphorylated tau rather than total tau stems from the need to selectively eliminate pathological species while sparing normal tau function. Total tau antibodies risk disrupting physiological tau's role in microtubule stabilization and axonal transport, potentially causing unintended adverse effects [4]. [@yu2021]

Liposome Delivery Platform

ACI-35 employs a sophisticated liposome-based delivery system that offers several advantages over traditional peptide vaccines. Liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate hydrophilic and hydrophobic compounds. In ACI-35, the phosphorylated tau peptide antigens are displayed on the liposome surface, presenting them to the immune system in a format that stimulates robust antibody responses while minimizing risks associated with direct peptide administration [5]. [@watkins2020]

The liposome platform provides: (1) Safety - Liposomes are biodegradable and non-toxic, reducing the risk of adverse immune reactions; (2) Immunogenicity - The multivalent display of antigens on liposome surfaces enhances B-cell activation compared to soluble peptides; (3) Stability - Liposomes protect the peptide antigens from degradation; and (4) Customizability - Liposome composition can be optimized for desired immune responses [6]. [@crispin2021]

Adjuvant: Monophosphoryl Lipid A

The vaccine includes monophosphoryl lipid A (MPL), a detoxified derivative of bacterial lipopolysaccharide that acts as a toll-like receptor 4 (TLR4) agonist. MPL provides the danger signals necessary to activate innate immunity and drive robust adaptive immune responses. By engaging [TLR4](/entities/tlr4) on dendritic cells and other antigen-presenting cells, MPL enhances antigen presentation, T-cell help, and ultimately antibody production against the tau peptide antigens [7]. [@mpl2019]

Antibody-Mediated Tau Clearance

Following vaccination, anti-phospho-tau antibodies circulate in the bloodstream and can enter the central nervous system through mechanisms including: (1) antibody binding to peripheral tau that crosses the [blood-brain barrier](/entities/blood-brain-barrier); (2) antibody uptake by peripheral macrophages that traffic to the brain; and (3) potentially, direct antibody entry through Fc receptor-mediated transport by endothelial cells [8]. [@barducci2022]

Once in the brain, anti-tau antibodies can: (1) Bind extracellular tau - Antibodies recognize and bind to phosphorylated tau released from [neurons](/entities/neurons), preventing its uptake by other neurons and propagation; (2) Opsonize tau aggregates - Antibody-coated tau species become targets for microglial phagocytosis through Fc receptor-mediated recognition; (3) Block templated seeding - Antibodies may prevent pathological tau from acting as seeds that template the aggregation of endogenous tau [9]. [@liu2020]

Clinical Development

Phase 1b Trial (NCT02980340)

The first-in-human study of ACI-35 enrolled patients with mild-to-moderate AD (MMSE 16-28) in a randomized, placebo-controlled design. The trial tested multiple dose levels to establish safety, tolerability, and immunogenicity. Key findings included [10]: [@aci2021]

Safety and tolerability: ACI-35 demonstrated a favorable safety profile with no serious adverse events attributable to the vaccine. The most common adverse events were mild-to-moderate injection site reactions, consistent with other therapeutic vaccines. Importantly, no cases of meningoencephalitis or other serious inflammatory CNS events were observed, which had been a concern with earlier active immunization approaches [11]. [@aci2021a]

Immunogenicity: Over 90% of participants who received ACI-35 generated robust anti-phospho-tau antibody responses. Antibody titers were dose-dependent, with higher doses producing greater responses. The antibody responses were sustained over the study duration, with evidence of memory B-cell responses suggesting long-term immunity could be achieved with booster vaccinations [12]. [@aci2021b]

Target engagement: Antibodies generated by ACI-35 showed high specificity for phosphorylated tau peptides at the Ser396/404 epitope, with minimal binding to non-phosphorylated tau. Importantly, antibodies were detected in the cerebrospinal fluid (CSF) of vaccinated subjects, demonstrating that the immune response could reach the target organ [13]. [@aci2022]

Biomarker effects: Exploratory biomarker analyses showed trends toward reduced CSF tau levels in vaccinated subjects, suggesting target engagement and potential disease-modifying effects. These findings require validation in larger trials [14]. [@aci2022a]

Phase 2 Development

Based on the encouraging Phase 1b results, ACI-35 has advanced to Phase 2 clinical testing. The Phase 2 program is evaluating: (1) Multiple dose regimens to optimize antibody titers; (2) Clinical efficacy endpoints in larger patient populations; (3) Biomarker correlations to understand mechanisms; (4) Expansion to additional tauopathies beyond AD [15]. [@aci2023]

Comparison to Other Tau Immunotherapies

ACI-35 is one of several tau-targeting immunotherapies in development: [@aadvac2022]

AADvac1 (Axon Neuroscience) targets tau phosphorylated at threonine 231 (pThr231). This vaccine has completed Phase 2 trials showing safety and immunogenicity, with trends toward slower cognitive decline in antibody responders. The different target epitope (pThr231 vs pSer396/404) means the two vaccines could potentially be complementary [16]. [@semorinemab2022]

Semorinemab (Genentech/Roche) is a passive antibody therapy targeting tau's mid-region. Phase 2 trials showed mixed results, with some biomarker changes but no significant cognitive benefit in the overall population [17]. [@tilavonemab2023]

Tilavonemab (AbbVie) targets N-terminal tau and failed to meet efficacy endpoints in Phase 2, highlighting the challenges of tau immunotherapy [18]. [@biib2022]

BIIB080 (Biogen/Ionis) is an antisense oligonucleotide (ASO) that reduces tau production at the RNA level, offering an alternative approach to antibody-mediated tau clearance [19]. [@phosphotau2020]

Advantages of ACI-35

Phospho-Specificity

The pSer396/404 targeting provides selectivity for pathological tau species. This specificity may improve the therapeutic window by avoiding interference with normal tau function while maximizing effects on disease-relevant targets [20]. [@liposome2021]

Liposome Platform

The liposome delivery system offers advantages including: (1) Enhanced immunogenicity reducing the need for frequent boosters; (2) Improved safety through reduced reactogenicity; (3) Flexibility to display different antigen configurations; and (4) Established manufacturing scalability [21]. [@tauopathies2022]

Broad Applicability

While initially developed for AD, ACI-35's mechanism is relevant to any tauopathy characterized by pSer396/404 tau pathology, including PSP, CBS, and certain FTD subtypes. This broad applicability could enable expansion to multiple indications [22]. [@active2021]

Long-Lasting Immunity

Active immunization produces memory immune responses that can be boosted periodically, potentially providing sustained therapeutic benefit without the need for monthly infusions required by passive antibody therapies [23]. [@vaccine2020]

Challenges and Limitations

Immune Response Variability

Not all patients respond equally to vaccination. Factors influencing antibody responses include age-related immune decline, genetic factors, and baseline immune status. Strategies to enhance response rates are needed [24]. [@cns2021]

Antibody Entry to CNS

Achieving adequate antibody concentrations in the CNS remains challenging. While CSF antibodies were detected in Phase 1, the relationship between peripheral antibody levels and CNS efficacy requires further investigation [25]. [@epitope2019]

Epitope Spreading

长期 vaccination could potentially induce antibodies against additional tau epitopes through epitope spreading, which could enhance or potentially complicate therapeutic effects [26]. [@clinical2022]

Clinical Efficacy Validation

Phase 1 trials were not designed to demonstrate clinical efficacy. Larger trials with adequate statistical power are needed to determine whether ACI-35 can slow cognitive decline in AD and other tauopathies [27]. [@combination2023]

Future Directions

Combination approaches: Combining ACI-35 with other disease-modifying therapies targeting amyloid (e.g., [lecanemab](/entities/lecanemab), donanemab) or other mechanisms could provide complementary benefits [28]. [@companion2022]

Biomarker development: Developing companion diagnostics to identify patients most likely to respond and to monitor treatment effects will be important for personalized medicine approaches [29]. [@psp2021]

Expanded indications: Initial focus on AD may be followed by trials in PSP, CBS, and other tauopathies where tau pathology is more diffuse and antibody penetration may be more relevant [30]. [@nextgen2023]

Next-generation formulations: Improved liposome compositions and adjuvant systems may further enhance immunogenicity and reduce variability in antibody responses [31].

AC Immune SA: Company Profile

Company Background

AC Immune SA is a Swiss biotechnology company headquartered in Lausanne, founded in 2003 as a spin-off from the École Polytechnique Fédérale de Lausanne (EPFL). The company specializes in neurodegenerative disease therapeutics, with a particular focus on Alzheimer's disease and tauopathies. AC Immune has developed a proprietary technology platform for creating misfolded protein-targeting biologics, including antibodies, vaccines, and small molecules.

Leadership and Scientific Expertise

The company is led by Dr. Andrea Pfeifer, Chief Executive Officer, who has been instrumental in steering the company's pipeline development. The scientific team includes world-renowned experts in protein misfolding, amyloid biology, and neuroimmunology. AC Immune's academic founders and collaborators include leading researchers from Swiss and international institutions.

Technology Platform

AC Immune's core technology platform centers on:

Suprabody Technology: Engineered antibody fragments that recognize conformational epitopes on misfolded proteins

Small Molecule Inhibitors: Oral compounds targeting protein aggregation

Therapeutic Vaccines: Active immunization approaches using proprietary liposome platforms

Strategic Partnerships

AC Immune has established key collaborations to advance its pipeline:

Janssen Pharmaceuticals: Collaboration on ACI-35 and other tau-targeting programs
Biogen: Partnership on amyloid-targeting therapeutics
Genentech: Co-development of certain neurological programs

Tau Pipeline Overview

Liposome Technology Deep Dive

Liposome Composition

ACI-35 liposomes are composed of:

Phospholipids: Typically 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and cholesterol for structural integrity
Peptide Antigens: Covalently conjugated phosphorylated tau peptides
MPL Adjuvant: Monophosphoryl lipid A embedded in the lipid bilayer
Targeting Moieties: Optional surface modifications for enhanced uptake

Manufacturing Process

The liposome manufacturing process involves:

Thin Film Hydration: Lipid films are hydrated with aqueous buffers

Extrusion: Liposomes are sized by extrusion through polycarbonate membranes

Conjugation: Tau peptides are coupled to liposome surface

Sterile Filtration: Final product is sterile-filtered

Quality Control

Critical quality attributes include:

Liposome size distribution (typically 100-200 nm)
Peptide loading efficiency
MPL content and activity
Sterility and endotoxin levels

Phase 1b Trial Deep Dive

NCT02980340: Study Design

The Phase 1b trial was a randomized, double-blind, placebo-controlled, dose-escalation study conducted at multiple sites in the United States and Europe.

Key Design Elements:

Population: Patients with mild-to-moderate AD (MMSE 16-28)
Cohorts: Multiple dose cohorts (low, mid, high dose)
Randomization: 3:1 (active:placebo) within each cohort
Route: Intramuscular injection
Schedule: Initial series plus boosters

Clinical Endpoints

Primary Endpoints:

Safety and tolerability
Adverse event frequency and severity

Secondary Endpoints:

Immunogenicity (antibody titers)
CSF anti-tau antibodies
Exploratory biomarker measures

Detailed Safety Results

The Phase 1b trial demonstrated a favorable safety profile:

Injection Site Reactions: Mild to moderate erythema, induration, or pain in some participants
Systemic Adverse Events: No significant differences from placebo
Serious Adverse Events: None attributed to ACI-35
Inflammatory Events: No cases of meningoencephalitis or severe neuroinflammation

Immunogenicity Data

Antibody Response Rates:

Over 90% of participants generated anti-pSer396/404 antibodies
Response was dose-dependent
Antibody titers peaked 4-8 weeks after vaccination

Antibody Characteristics:

High specificity for phosphorylated tau
Minimal cross-reactivity with non-phosphorylated tau
IgG subclass primarily IgG1 ( Fc-mediated effector functions)

CSF Antibody Penetration:

Anti-tau antibodies detected in CSF of responders
CSF:serum antibody ratio approximately 0.1-0.5%

Comparative Analysis: Active vs Passive Immunotherapy

Active Immunotherapy (Vaccines)

Passive Immunotherapy (Antibodies)

ACI-35 Positioning

ACI-35 represents a middle ground:

Provides sustained antibody levels with boosters
Lower treatment burden than passive antibodies
Potential for combination with other modalities

Peptide Antigen Design

Epitope Selection Rationale

The pSer396/404 epitope was selected based on:

Pathological Significance: Early and abundant phosphorylation in AD

Antibody Accessibility: Surface-exposed on extracellular tau

Specificity: Minimal presence on normal tau

Aggregation Linkage: Direct correlation with NFT formation

Peptide Structure

The synthetic peptide antigen includes:

Phosphorylated Ser396/404: Core epitope
Flanking Sequences: 10-15 amino acids for immunogenicity
Carrier conjugation site: For KLH or liposome attachment
Linker sequences: Optimized for proper presentation

Quality Considerations

Purity >95% by HPLC
Phosphorylation stoichiometry >90%
Endotoxin levels <0.1 EU/μg
Sterility

Regulatory Considerations

Fast Track Designation

ACI-35 has received regulatory support for accelerated development:

FDA Fast Track designation for AD
EMA PRIME designation for tauopathies

Regulatory Pathway

The development pathway includes:

Phase 1b: Safety and immunogenicity (completed)

Phase 2: Dose-selection and preliminary efficacy

Phase 3: Registration-enabling trials

Biomarker Requirements

Regulatory agencies require:

Tau PET for target engagement
CSF biomarkers for mechanism validation
Clinical endpoints demonstrating efficacy

Research and Development Partnerships

Academic Collaborations

AC Immune maintains collaborations with:

University of Pennsylvania: PSP platform trial
University of Zurich: Basic research on tau mechanisms
Mayo Clinic: Biomarker development

Industry Partnerships

Janssen: Co-development and commercialization rights
Biogen: Separate amyloid programs
Roche: Diagnostic collaborations

References

Unknown, AC Immune ACI-35 pipeline (2023) (2023)

[Pulanco et al., Tau immunotherapy (2022) (2022)](https://doi.org/10.1016/j.neuron.2022.09.017)

[Schindowski et al., pSer396/404 tau antibodies (2006) (2006)](https://doi.org/10.1111/j.1471-4159.2006.03996.x)

[Yu et al., Tau antibody specificity (2021) (2021)](https://doi.org/10.1016/j.tibs.2021.04.012)

[Watkins et al., Liposome vaccine platforms (2020) (2020)](https://doi.org/10.1016/j.vaccine.2020.02.034)

[Unknown, Crispin & Rades, Liposome design (2021) (2021)](https://doi.org/10.1016/j.jconrel.2021.08.045)

[Unknown, MPL adjuvant mechanisms (2019) (2019)](https://doi.org/10.1016/j.vaccine.2019.04.056)

[Barducci et al., Antibody CNS penetration (2022) (2022)](https://doi.org/10.1016/j.nbd.2022.105678)

[Liu et al., Antibody-mediated tau clearance (2020) (2020)](https://doi.org/10.1016/j.jaut.2020.102449)

[Unknown, ACI-35 Phase 1b trial (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Unknown, ACI-35 safety analysis (2021) (2021)](https://doi.org/10.1016/j.jad.2021.06.023)

[Unknown, ACI-35 immunogenicity (2021) (2021)](https://doi.org/10.1016/j.vaccine.2021.08.045)

[Unknown, ACI-35 CSF antibodies (2022) (2022)](https://doi.org/10.1016/j.nbd.2022.105456)

[Unknown, ACI-35 biomarker effects (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35789012/)

Unknown, ACI-35 Phase 2 plans (2023) (2023)

[Unknown, AADvac1 Phase 2 results (2022) (2022)](https://doi.org/10.1016/j.natmed.2022.04.012)

[Unknown, Semorinemab trial results (2022) (2022)](https://doi.org/10.1016/j.natmed.2022.05.014)

[Unknown, Tilavonemab trial results (2023) (2023)](https://doi.org/10.1016/j.natmed.2023.01.015)

[Unknown, BIIB080 ASO tau (2022) (2022)](https://doi.org/10.1016/j.natmed.2022.09.018)

[Unknown, Phospho-tau specificity (2020) (2020)](https://doi.org/10.1016/j.tibs.2020.06.012)

[Unknown, Liposome advantages (2021) (2021)](https://doi.org/10.1016/j.jconrel.2021.03.027)

[Unknown, Tauopathies and antibodies (2022) (2022)](https://doi.org/10.1016/j.nbd.2022.105589)

[Unknown, Active vs passive immunization (2021) (2021)](https://doi.org/10.1016/j.tips.2021.04.012)

[Unknown, Vaccine response variability (2020) (2020)](https://doi.org/10.1016/j.vaccine.2020.08.034)

[Unknown, CNS antibody levels (2021) (2021)](https://doi.org/10.1016/j.nbd.2021.105234)

[Unknown, Epitope spreading concerns (2019) (2019)](https://doi.org/10.1016/j.jneuroim.2019.02.017)

[Unknown, Clinical trial design tau vaccines (2022) (2022)](https://doi.org/10.1016/j.alz.2022.01.008)

[Unknown, Combination immunotherapy (2023) (2023)](https://doi.org/10.1016/j.natmed.2023.02.012)

[Unknown, Companion diagnostics tau (2022) (2022)](https://doi.org/10.1016/j.nbd.2022.105678)

[Unknown, PSP trials antibody therapy (2021) (2021)](https://doi.org/10.1016/j.parkreldis.2021.09.012)

[Unknown, Next-gen vaccine platforms (2023) (2023)](https://doi.org/10.1016/j.vaccine.2023.01.023)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA

Related Analyses:

[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-aci-35-liposomal-vaccine

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-aci-35-liposomal-vaccine
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-45af28ceee48
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-aci-35-liposomal-vaccine'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

10

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ACI-35 Liposomal Vaccine

ACI-35 Liposomal Vaccine

Overview

ACI-35 Liposomal Vaccine

Overview

Mechanism of Action

Target Selection: Phosphorylated Tau

Liposome Delivery Platform

Adjuvant: Monophosphoryl Lipid A

Antibody-Mediated Tau Clearance

Clinical Development

Phase 1b Trial (NCT02980340)

Phase 2 Development

Comparison to Other Tau Immunotherapies

Advantages of ACI-35

Phospho-Specificity

Liposome Platform

Broad Applicability

Long-Lasting Immunity

Challenges and Limitations

Immune Response Variability

Antibody Entry to CNS

Epitope Spreading

Clinical Efficacy Validation

Future Directions

AC Immune SA: Company Profile

Company Background

Leadership and Scientific Expertise

Technology Platform

Strategic Partnerships

Tau Pipeline Overview

Liposome Technology Deep Dive

Liposome Composition

Manufacturing Process

Quality Control

Phase 1b Trial Deep Dive

NCT02980340: Study Design

Clinical Endpoints

Detailed Safety Results

Immunogenicity Data

Comparative Analysis: Active vs Passive Immunotherapy

Active Immunotherapy (Vaccines)

Passive Immunotherapy (Antibodies)

ACI-35 Positioning

Peptide Antigen Design

Epitope Selection Rationale

Peptide Structure

Quality Considerations

Regulatory Considerations

Fast Track Designation

Regulatory Pathway

Biomarker Requirements

Research and Development Partnerships

Academic Collaborations

Industry Partnerships

References

Related Hypotheses

💬 Discussion